Sutro Biopharma Inc STRO-002 Update Transcript
Greetings, and welcome to the Sutro Biopharma webcast. (Operator Instructions) Please note, this conference is being recorded.
I will now turn the conference over to our host, Ed Albini, Chief Financial Officer. Thank you. You may begin.
Thank you, operator. Good afternoon, everyone, and thank you for joining us. With me on the call are Bill Newell, Chief Executive Officer; Dr. Stan Frankel, an esteemed member of our Scientific Advisory Board; Dr. Trevor Hallam, President of Research and Chief Scientific Officer; and Jane Chung, Chief Commercial Officer.
We also welcome on the line Dr. R. Wendel Naumann of the Levine Cancer Institute at Atrium Health. This afternoon, we issued a news release that you can find on our website at www.sutrobio.com, which includes an update from our Phase I Dose-Expansion study of STRO-002, also known as Luveltamab Tazevibuli or luvelta in ovarian cancer as well as our plans moving forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
